A cohort study performed a nested case-control analysis using data from the PharMetrics Plus database from January 1, 2006, to December 31, 2020. Researchers followed up with cohort members until coverage termination or first diagnosis of ION, RVO, or SRD. Four controls per case were matched, adjusting for potential confounding variables. Cases with corresponding ocular diagnoses in the year before the cohort were excluded. Adjusted incidence rate ratios (IRRs) with 95% confidence intervals were calculated using conditional logistic regression, controlling for coronary artery disease (CAD), diabetes, hypertension, and smoking for all outcomes, and sleep apnea for the ION outcome.
Patients with all outcomes were more likely to experience CAD, diabetes, hypertension, and sleep apnea. For the composite endpoints of any of the outcomes, the adjusted IRR was 1.85. For RVO, ION, and SRD as individual outcomes, the adjusted IRRs were 1.44, 2.02, and 2.58, respectively. The researchers concluded that regular users of PDE5is might have an increased risk for all outcomes, although more cases of SRD were found.
Learn more about PDE5is.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Bradley Schwartz. Rapid Review Quiz: Erectile Dysfunction - Medscape - Aug 17, 2022.